Chest Diseases Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Diagnostic Radiology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
BMC Pulm Med. 2024 Feb 14;24(1):86. doi: 10.1186/s12890-024-02883-4.
The new endobronchial therapy called biological lung volume reduction (BioLVR) involves using a rapid polymerizing sealant to block off the most emphysematous portions of the lungs. The primary mechanism of action is resorption atelectasis, which is then followed by inflammation and remodeling of the airspace. The remodeling process will result in the formation of scars, leading to the contraction of the lung tissue. As a result, a decrease in functional lung volume is anticipated for a period of 6-8 weeks.
Assessing the safety and effectiveness of bronchoscopic installation of (fibrinogen and thrombin) in COPD patients with homogeneous emphysema in terms of radiological, physiological, and quality of life outcomes.
Between December 2017 and December 2019, 40 COPD patients with homogeneous emphysema were studied using a fiber optic bronchoscope while they were awake but sedated. Tanta University Hospitals' chest medicine department collaborated with the diagnostic radiology department of the Faculty of Medicine.
All the following parameters were reduced from their initial values: HRCT volumetry, RV/TLC, mMRC dyspnea scale, CAT score, 6MWT, FEV1, and the FEV1/FVC ratio at the first, third, and sixth months from the beginning (p = 0.001). One individual (0.025%) had pneumonia, whereas three individuals had COPD (0.075%). Using fibrin glue produced locally, biological lung volume reduction (Bio LVR) may be an effective treatment for advanced homogenous emphysema.
By using locally prepared fibrin glue the biologic lung volume reduction (Bio LVR) may be a convenient method to treat advanced homogenous emphysema.
新型支气管内治疗方法——生物肺减容术（BioLVR），涉及使用快速聚合密封剂来阻塞肺部最气肿的部分。其主要作用机制是吸收肺不张，随后发生气腔炎症和重塑。重塑过程会导致疤痕形成，导致肺组织收缩。因此，预计在 6-8 周内会出现功能性肺容积减少。
评估纤维蛋白原和凝血酶在 COPD 患者中治疗均匀性肺气肿的安全性和有效性，通过影像学、生理学和生活质量结果进行评估。
2017 年 12 月至 2019 年 12 月，40 例均匀性肺气肿的 COPD 患者在纤维光学支气管镜下清醒镇静状态下进行研究。坦塔大学医院胸内科与医学院放射诊断科合作。
所有以下参数均从初始值降低：HRCT 体积、RV/TLC、mMRC 呼吸困难评分、CAT 评分、6MWT、FEV1 以及 FEV1/FVC 比值，在开始后的第一个、第三个和第六个月（p = 0.001）。1 人（0.025%）发生肺炎，3 人（0.075%）发生 COPD。使用局部制备的纤维蛋白胶进行生物肺减容术（Bio LVR）可能是治疗晚期均匀性肺气肿的有效方法。
使用局部制备的纤维蛋白胶进行生物肺减容术（Bio LVR）可能是治疗晚期均匀性肺气肿的一种简便方法。
